Latest news

Thumbnail image for NICE backs Bayer’s Xarelto

NICE backs Bayer’s Xarelto

The decision is based on evidence from the COMPASS study, which was stopped early after meeting its primary efficacy endpoint.

2nd August 2019

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download